Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 15, 22 | -0.47 | -0.57
Increased by
+17.54%
|
| May 13, 22 | -0.93 | -0.82
Decreased by
-13.41%
|
| Nov 15, 21 | -0.98 | -0.74
Decreased by
-32.43%
|
| Sep 20, 21 | -0.18 | -0.80
Increased by
+77.50%
|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 22 | 0.00
Decreased by
N/A%
|
-50.99 M
Decreased by
-31.76%
|
Decreased by
N/A%
Decreased by
N/A%
|
| Mar 31, 22 | 0.00
Decreased by
N/A%
|
-100.67 M
Decreased by
-109.69%
|
Decreased by
N/A%
Decreased by
N/A%
|
| Dec 31, 21 | 0.00 - | -140.02 M - |
Decreased by
N/A%
-
|
| Sep 30, 21 | 3.00 - | -60.38 K - |
Decreased by
-2.01 M%
-
|
| Mar 31, 21 | 0.00 - | -38.70 M - |
Decreased by
N/A%
-
|
| Sep 30, 20 | 0.00 - | -48.01 M - |
Decreased by
N/A%
-
|
| Rank | ETF | Shares | Market Value | Weight % in ETF |
|---|
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.